OCN Oncology Pharmacology 3

Question 1

Immune-related adverse events (irAEs) from checkpoint inhibitors most commonly affect which organ systems?

Accepted Answer

Skin, GI tract, liver, and endocrine glands

Answer

Bone marrow only

Answer

Heart and kidneys only

Answer

Brain exclusively

Question 2

PARP inhibitors such as olaparib are most effective in cancers with defects in which pathway?

Accepted Answer

Homologous recombination repair (BRCA1/2 mutations)

Answer

VEGF signaling pathway

Answer

PI3K/AKT/mTOR pathway

Answer

RAS/MAPK signaling pathway

Question 3

CAR-T cell therapy requires which critical patient preparation step?

Accepted Answer

Lymphodepleting chemotherapy before infusion

Answer

High-dose steroid premedication only

Answer

Bone marrow biopsy on day of infusion

Answer

Complete fasting for 24 hours

Question 4

Cytokine release syndrome (CRS) is a potentially life-threatening complication most associated with which therapies?

Accepted Answer

CAR-T cell therapy and bispecific antibodies

Answer

Alkylating chemotherapy

Answer

Hormone therapy

Answer

Oral targeted therapy

Question 5

Which agent is used as antidote or reversal for severe methotrexate toxicity when leucovorin is insufficient?

Accepted Answer

Glucarpidase (carboxypeptidase G2)

Answer

N-acetylcysteine

Answer

Dexrazoxane

Answer

Mesna

Question 6

Which drug requires REMS (Risk Evaluation and Mitigation Strategy) program enrollment due to teratogenicity in oncology?

Accepted Answer

Thalidomide and lenalidomide

Answer

Methotrexate alone

Answer

Ondansetron

Answer

Filgrastim